Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study

Overview of attention for article published in Revista Brasileira de Terapia Intensiva, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 2 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 4,476 followers.

RT @LosiggioRosario: #5 #DEFENDERtrial 📌Dapagliflozin in Patients with Critical Illness 👥507 pts 🔀Arms: Dapagliflozin 10 mg daily vs stan…

26 Feb 2024

Reply Repost Favourite

#5 #DEFENDERtrial 📌Dapagliflozin in Patients with Critical Illness 👥507 pts 🔀Arms: Dapagliflozin 10 mg daily vs standard of care ➡️Composite primary outcome: Hospital mortality, initiation of KRT, ICU length of stay 🔗 https://t.co/ay5rEQw7mQ @f_g_zampi

26 Feb 2024

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.